The transaction is expected to close in the first half of 2025, subject to the satisfaction of customary closing conditions.

The Dundalk site was WuXi's first manufacturing investment in Europe and the company’s first investment of this scale outside ...

Pharmaceutical firm MSD has agreed a deal to buy the WuXi Vaccines manufacturing facility in Dundalk, Co Louth as part of its ...

US pharmaceutical group adds eighth Irish manufacturing site to its network as it promises to deliver 1,000 jobs this year ...

The pharmaceutical firm MSD is buying out the WuXi Vaccines manufacturing plant in Dundalk, in a €500m deal. The American ...

MSD's acquisition of the WuXi Dundalk site strengthens the company’s long-standing commitment to Ireland, bringing its ...

MSD has spent €500M acquiring a Dundalk vaccine plant and several other facilities around Ireland in an early year boost for ...

China's WuXi Biologics has confirmed it will sell its vaccine facility in Ireland to US drugmaker Merck & Co for about €500 ...

News that pharmaceutical company MSD Ireland has acquired the WuXi Vaccines manufacturing facility in Dundalk has been ...

MSD acquires WuXi Vaccines' Dundalk facility with a €500 million investment, creating 1,000 new jobs across Ireland and ...

US multinational pharmaceutical company MSD has today (6 January) announced the acquisition of WuXi Vaccines’ Dundalk site.

In Ireland, WuXi Biologics has sold a new vaccines plant to Merck & Co. for €500 million ($521 million). The New Jersey ...